Case Control Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Mar 6, 2021; 9(7): 1524-1531
Published online Mar 6, 2021. doi: 10.12998/wjcc.v9.i7.1524
Table 1 Differences in the expression of Runx3 and Ki-67 from the biopsy between two groups before and after the treatment, n (%)
GroupsnTime pointRunx3
Ki-67
Positive
Negative
Positive
Negative
Observation group50Before the treatment26 (2.0)24 (48.0)46 (92.0)4 (8.0)
After the treatment38 (76.0)a12 (24.0)37 (74.0)a12 (26.0)
Control group50Before the treatment27 (54.0)23 (46.0)45 (90.0)5 (10.0)
After the treatment34 (68.0)a16 (32.0)36 (72.0)a14 (28.0)
Table 2 Differences in the incidence of chemoradiotherapy-induced adverse reactions between the two groups before the operation, n (%)
Groups
n
Anemia
Leukopenia
Thrombocytopenia
Neutropenia
Diarrhea
Fatigue
Neurotoxicity
Nausea and vomiting
Observation group5024 (48.0)31 (62.0)a36 (72.0)a31 (62.0)a17 (34.0)a9 (18.0)11 (22.0)23 (46.0)
Control group5022 (44.0)20 (40.0)24 (48.0)22 (44.0)9 (18.0)8 (16.0)12 (24.0)22 (24.0)
Table 3 Comparison of operation indices between the two groups, n (%)
GroupsnDuration of surgery (min)Intraoperative blood loss (mL)Anal conservation ratePostoperative complications
Surgery incision infection
Anastomotic leakage
Intestinal obstruction
Observation group50234.12 ± 24.56124.78 ± 15.9045 (90.0)2 (4.0)3 (6.0)2 (4.0)
Control group50215.34 ± 26.71113.61 ± 16.2244 (88.0)3 (6.0)4 (8.0)1 (2.0)
t/χ2 value1.211.980.280.110.190.21
P value0.540.210.750.870.830.74